6 years ago

MGB Biopharma Secures Funding for Antibiotic Resistance Research

  • MGB Biopharma, a Glasgow, Scotland-based biopharmaceutical company developing a novel class of anti-infectives to address antibiotic resistance, has completed its latest funding round

  • The round was led by Archangel Investors with participation from Scottish Investment Bank, Barwell and TriCapital Investors

  • The company intends to use the funds to complete all activities around its ongoing Phase IIa clinical trial with its lead antibiotic MGB-BP-3 and prepare for the next stages of its development.

      • ProblemHealthcare

      "Antibiotic resistance is a growing global health threat, and there is an urgent need for new antibiotics to treat infections caused by drug-resistant bacteria."

      Solution

      "MGB Biopharma is developing a novel class of anti-infectives that target a different mechanism of action than traditional antibiotics, making them effective against drug-resistant bacteria. Their lead candidate, MGB-BP-3, is being developed as an oral treatment for Clostridium difficile-associated diarrhoea (CDAD)."

      Covered on